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Background To assess the prognostic value of mineralocorticoid receptor antagonist (MRA) initiation and change in serum
potassium (K+) during follow-up in patients post-acute myocardial infarction with left ventricular dysfunction or
chronic heart failure (HF) and reduced ejection fraction (HFrEF).
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Methods
and results
Risk scores for predicting cardiovascular death (primary outcome), hospitalization for HF and all-cause death were
developed. K+ and other relevant time-updated clinical and biological variables were added to conventional prognostic
factors when constructing these new models. EPHESUS (n = 6632) was the derivation cohort, while EMPHASIS-HF
(chronic HF, n = 2737) was used as external validation cohort. The final cardiovascular death risk score included
medical history, clinical and biological parameters (e.g. K+, below or above the normal range of 4–5 mmol/L,
estimated glomerular filtration rate, and anaemia), as well as aspects of treatment (any diuretic usage, MRA use or
discontinuation, and beta-blocker use). The risk score performed well in both the derivation and validation cohorts
and outperformed the MAGGIC score. A web-based calculator was created to allow easy determination of the risk
score (http://cic-p-nancy.fr/CardiovascularriskscoreCalculator/).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Adding time-updated variables, including K+ and MRA treatment, improved risk prediction of cardiovascular death
(on top of the MAGGIC score) in patients with HF eligible for renin–angiotensin system inhibitors and MRA
therapy. This new risk score including MRA usage and K+ may be of value in helping physicians to better use MRAs,
avoid unnecessary and potentially detrimental permanent discontinuations, and therefore improving cardiovascular
outcomes in patients with chronic HFrEF or HF after acute myocardial infarction with left ventricular dysfunction.
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Introduction
Hypokalaemia and hyperkalaemia have been consistently shown
to be associated with increased morbidity and mortality in var-
ious populations [e.g. hypertension,1 acute2,3 and chronic heart
failure4,5 (HF), acute myocardial infarction (AMI),6,7 chronic kid-
ney disease, and the general population].8 There are few validated
predictors of the risk of cardiovascular (CV) death associated
with serum potassium (K+) abnormalities in HF patients receiving
renin–angiotensin–aldosterone system (RAAS) blockers. There-
fore, we have developed a score describing the risk of CV events
associated with serum K+ in patients receiving mineralocorticoid
receptor antagonist (MRA) therapy. This score could help clinicians
in decision-making regarding the safe and effective use of MRAs
in patients with HF and reduced ejection fraction (HFrEF) and in
those with left ventricular dysfunction and HF after AMI.
We took advantage of data collected in major clinical trials with




The design and main results of the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial
have previously been reported.9 The EPHESUS study enrolled 6632
patients with HF after AMI complicated by left ventricular systolic
dysfunction (ejection fraction <40%). Patients were entered into the
study from 3 to 14 days after AMI. All patients were randomly assigned
to treatment with eplerenone 25 mg/day or placebo.
The design, patient eligibility criteria, study procedure and main
results of the Eplerenone in Mild Patients Hospitalization and Survival
Study in Heart Failure (EMPHASIS-HF) trial have also been previously
reported.10 In this randomized double-blind trial, 2737 patients with
New York Heart Association (NYHA) class II HF and an ejection
fraction ≤35% were randomly assigned to receive eplerenone (up to
50 mg daily) or placebo, in addition to recommended therapy.
Statistical analysis
All analyses were performed using the R software (the R Foundation
for Statistical Computing, Vienna, Austria). Baseline characteristics of
these two populations were described using mean± standard deviation
for continuous variables and frequency (percentage) for categorical
variables.
Candidate variables are listed in online supplementary
Methods S1.11,12 Cox proportional hazards models with time-updated
covariates and interactive backward variable selection were used to
build risk scores for the three following endpoints: (i) CV death, (ii)
hospitalization for HF, and (iii) all-cause death. A P< 0.05 was used
to remove non-significant variables from the Cox model. Hazard
ratios (HR) are presented with their 95% confidence intervals. A
points-based risk scoring system was derived from each final Cox
model according to the following principle: points were attributed by
multiplying the regression coefficients by 10, then by rounding the
values to the nearest integer, and risk score was finally calculated as



















































































.. The predicted risk at 1 year was plotted as a function of the risk
score (more details on predicted risk calculation in online supplemen-
tary Methods S1). Risk score discrimination was assessed using the
Harrell’s c-index.13 As described in Ketchum et al.,14 predicted risk
at 1 year and 2 years by deciles of risk score was plotted against the
observed risk estimated by the Kaplan–Meier method from which a
correlation coefficient was calculated. The calibration of the model was
assessed using the Hosmer–Lemeshow goodness of fit test.15
As a supplementary analysis, we evaluated the effect <30 days and
≥ 30 days after measurement for each clinical/biological time-updated
variable and reported corresponding P-value for interaction.
Results
The baseline characteristics of patients in EPHESUS and
EMPHASIS-HF are presented in Table 1. The median [interquartile
range (IQR)] follow-up was 16 (12–20) months in EPHESUS and
21 (10–33) in EMPHASIS-HF. The anticipated number of serum
K+ measurements according to the protocol was 10 (8–11) and
7 (5–10) in each trial, respectively. The median (IQR) number
of actual serum K+ measurements was 11 (9–13) and 8 (5–11),
respectively, i.e. some additional measurements were performed
after a clinical event or after a non-anticipated medication change.
The median (IQR) number of serum K+ measurements per year
per patient was 8.2 (7.0–10.2) and 4.5 (3.9–6.1), respectively.
Table 2 shows the predictive models for CV death and hospital-
ization for HF and how the risk score is derived (online supple-
mentary Table S1 also presents the model for all-cause death). The
CV death score included certain aspects of medical history, clinical
variables (age, systolic blood pressure, heart rate, body mass index,
NYHA class) and biological parameters [e.g. serum K+, below or
above a normal range of 4–5 mmol/L, estimated glomerular filtra-
tion rate (eGFR), anaemia] and certain treatments (diuretic use,
MRA current use or discontinuation, beta-blocker use). Figure 1
presents the 1-year predicted risk of CV death and hospitalization
for HF, according to score, while online supplementary Figure S1
presents the 1-year predicted risk of all-cause death.
Discrimination and calibration of the
model in derivation and validation
cohorts
The model performed well in both the derivation and validation
cohorts. The C-indexes for the CV risk and HF hospitalization
scores in EPHESUS ranged from 0.78 to 0.79 and were approxi-
mately 0.75 for each endpoint in EMPHASIS-HF (Table 2). Figure 2
presents the predicted compared with observed risks (CV death,
hospitalization for HF), by deciles of risk score, in the derivation
and validation cohorts at 1 and 2 years. The correlation coeffi-
cients between predicted and observed survival were very high
(close to 0.99) in both derivation and validation cohorts. The
Hosmer–Lemeshow goodness of fit statistic confirmed model
accuracy in the EPHESUS derivation (P = 0.99 for CV death
and 0.91 for HF hospitalization) at 1 year. In the EMPHASIS-HF
cohort, a slight overestimation of predicted risk of CV death
was observed at 1 year (P = 0.057), which was not the case for
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Table 1 Baseline characteristics and outcomes of EPHESUS and EMPHASIS-HF patients
EPHESUS (n = 6632) EMPHASIS-HF (n = 2737)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristics n Mean±SD/n (%) n Mean±SD/n (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 6632 64±12 2737 69± 8
Gender 6632 2737
Male 4714 (71.1) 2127 (77.7)
Female 1918 (28.9) 610 (22.3)
Cigarette smoking status 6627 2737
Never smoker 2587 (39.0) 1223 (44.7)
Current smoker 2043 (30.8) 293 (10.7)
Former smoker 1997 (30.1) 1221 (44.6)
History of alcohol abuse 6615 83 (1.3) 2737 16 (0.6)
Body mass index (kg/m2) 6611 27.4± 4.5 2724 27.5± 4.9
Systolic BP (mmHg) 6630 119±16 2736 124± 17
Diastolic BP (mmHg) 6630 72±11 2736 75±10
Heart rate (bpm) 6628 75±12 2735 72±12
Potassium (mmol/L) 6586 4.3± 0.4 2731 4.3± 0.4
eGFR (mL/min/1.73 m2) 6587 68± 21 2725 65±18
Haemoglobin (g/dL) 6556 13.3±1.7 2669 13.8±1.6
Anaemia 6556 2160 (32.9) 2669 616 (23.1)
Medical history
Previous MI 6632 1802 (27.2) 2734 1380 (50.5)
Atrial fibrillation 6632 874 (13.2) 2737 844 (30.8)
Renal insufficiency 6632 434 (6.5) 2737 214 (7.8)
COPD 6632 625 (9.4) 2734 391 (14.3)
Previous hospitalization for HFa 6632 975 (14.7) 2734 1438 (52.6)
Hypertension 6632 4007 (60.4) 2737 1819 (66.5)
Diabetes 6632 2142 (32.3) 2737 859 (31.4)
Peripheral vascular disease 6632 823 (12.4) 2737 94 (3.4)
Medication
Any diuretic use 6632 3984 (60.1) 2721 2326 (85.5)
Beta-blocker use 6632 4961 (74.8) 2721 2374 (87.2)
ACEi use 6632 5616 (84.7) 2721 2124 (78.1)
ARB use 6632 216 (3.3) 2721 527 (19.4)
ACEi/ARB use 6632 5751 (86.7) 2721 2558 (94.0)
Study treatment 6632 2737
Placebo 3313 (50.0) 1373 (50.2)
Eplerenone 3319 (50.0) 1364 (49.8)
Study treatment taken or not at baseline 6632 2737
Not taken 24 (0.4) 7 (0.3)
Taken 6608 (99.6) 2730 (99.7)
Outcomes
All-cause death 6632 1032 (15.6) 2737 384 (14.0)
CV death 6632 890 (13.4) 2737 332 (12.1)
Hospitalization for HF 6632 855 (12.9) 2737 417 (15.2)
CV death/hospitalization for HF 6632 1451 (21.9) 2737 605 (22.1)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP blood pressure; COPD, chronic obstructive pulmonary disease; CV, cardiovascular;
eGFR, estimated glomerular filtration rate; HF, heart failure; MI myocardial infarction; SD, standard deviation.
aDefined as previous episodes of HF in the EPHESUS cohort.
hospitalization for HF (P = 0.25). At 2 years, the two risk scores
were well calibrated in the two cohorts (all P>0.30).
The risk scores significantly outperformed the Meta-Analysis
Global Group in Chronic Heart Failure (MAGGIC)16 score for
predicting outcomes in both EPHESUS (C-index difference of








. EMPHASIS-HF (C-index difference of 0.055 for CV death and
0.064 for hospitalization for HF) (online supplementary Table S2).
The distribution of risk score categories across the two trials is
presented in online supplementary Table S3.
A web-based application was created to allow an
easy determination of the complete risk score as a
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Table 2 Risk scores of cardiovascular death and hospitalization for heart failure developed in the EPHESUS cohort
and validated in the EMPHASIS-HF cohort
CV death Hospitalization for HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variables HR (95% CI) P–value 𝜷 Points HR (95% CI) P-value 𝜷 Points
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Time-updated variables
Potassium (mmol/L)
<3.5 2.09 (1.49–2.92) <0.0001 0.74 7 2.17 (1.48–3.19) <0.0001 0.78 8
3.5–3.9 1.30 (1.05–1.61) 0.017 0.26 3 1.50 (1.22–1.85) 0.0001 0.41 4
4–5 1.00 – – 0 1.00 – – 0
5.1–5.5 1.30 (1.04–1.62) 0.019 0.26 3 1.00 (0.79–1.27) 0.99 0.00 0
>5.5 2.10 (1.41–3.13) 0.0003 0.74 7 2.22 (1.51–3.26) <0.0001 0.80 8
eGFR (mL/min/1.73 m2)
<30 2.53 (1.76–3.62) <0.0001 0.93 9 2.24 (1.57–3.19) <0.0001 0.81 8
30–44 1.70 (1.24–2.34) 0.001 0.53 5 2.10 (1.58–2.79) <0.0001 0.74 7
45–59 1.31 (0.96–1.77) 0.084 0.27 3 1.51 (1.15–1.99) 0.003 0.41 4
60–89 1.16 (0.87–1.53) 0.31 0.15 1 1.09 (0.83–1.41) 0.54 0.08 1
≥90 1.00 – – 0 1.00 – – 0
Anaemia 1.20 (1.03–1.39) 0.020 0.18 2 1.77 (1.52–2.05) <0.0001 0.57 6
Body mass index (kg/m2)
<18.5 1.69 (1.01–2.81) 0.044 0.52 5 – – – –
18.5–24.9 1.34 (1.14–1.57) 0.0004 0.29 3 – – – –
25–29.9 1.00 – – 0 – – – –
≥30 1.04 (0.86–1.27) 0.66 0.04 0 – – – –
Systolic BP (mmHg)
<100 3.13 (2.44–4.00) <0.0001 1.14 11 1.99 (1.50–2.64) <0.0001 0.69 7
100–119 1.51 (1.23–1.85) <0.0001 0.41 4 1.52 (1.25–1.85) <0.0001 0.42 4
120–139 1.17 (0.95–1.43) 0.13 0.16 2 1.05 (0.87–1.28) 0.61 0.05 1
≥140 1.00 – – 0 1.00 – – 0
Heart rate (bpm)
≤60 1.00 – – 0 1.00 – – 0
61–80 1.08 (0.88–1.34) 0.46 0.08 1 1.35 (1.07–1.69) 0.010 0.30 3
81–100 1.75 (1.38–2.22) <0.0001 0.56 6 2.35 (1.83–3.01) <0.0001 0.85 9
>100 3.21 (2.23–4.61) <0.0001 1.17 12 4.04 (2.63–6.20) <0.0001 1.40 14
NYHA class
I 1.00 – – 0 1.00 – – 0
II 1.23 (1.00–1.51) 0.048 0.21 2 1.28 (1.05–1.56) 0.013 0.25 2
III/IV 3.22 (2.60–4.00) <0.0001 1.17 12 2.88 (2.33–3.55) <0.0001 1.06 11
Age (years)
<65 1.00 – – 0 – – – –
65–74 1.29 (1.07–1.56) 0.009 0.26 3 – – – –
≥75 1.39 (1.12–1.71) 0.002 0.33 3 – – – –
Permanent discontinuation of study treatment 1.66 (1.38–2.00) <0.0001 0.51 5 – – – –
Fixed variables (baseline)
Previous MI 1.24 (1.06–1.46) 0.007 0.22 2 1.38 (1.18–1.61) <0.0001 0.32 3
Atrial fibrillation 1.26 (1.06–1.49) 0.010 0.23 2 1.23 (1.03–1.46) 0.024 0.20 2
Previous hospitalization for HF 1.26 (1.06–1.51) 0.010 0.23 2 1.26 (1.05–1.50) 0.011 0.23 2
Hypertension – – – – 1.31 (1.11–1.54) 0.001 0.27 3
Diabetes 1.21 (1.04–1.41) 0.012 0.19 2 1.26 (1.08–1.46) 0.003 0.23 2
Peripheral vascular disease 1.34 (1.12–1.60) 0.002 0.29 3 1.37 (1.14–1.64) 0.0006 0.32 3
Any diuretic use 1.30 (1.09–1.55) 0.003 0.26 3 1.67 (1.39–2.00) <0.0001 0.51 5
No beta-blocker use 1.34 (1.16–1.56) <0.0001 0.30 3 – – – –
Study treatment
Eplerenone 0.84 (0.73–0.97) 0.017 −0.17 0 0.81 (0.70–0.93) 0.004 −0.21 0
Placebo/not on eplerenone 1.00 – – 2 1.00 – – 2
C-index (95% CI)
Derivation (EPHESUS) 0.783 (0.766–0.800) 0.781 (0.765–0.797)
Validation (EMPHASIS-HF) 0.747 (0.718–0.777) 0.743 (0.716–0.769)
BP, blood pressure; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; NYHA,
New York Heart Association.
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Figure 1 One-year predicted risk of cardiovascular (CV) death and hospitalization for heart failure (HF) as a function of risk score.
function of available parameters to the physician after
6 months, 1 year and 2 years. The calculator is available at
http://cic-p-nancy.fr/CardiovascularriskscoreCalculator/.
Interaction between the number
of potassium measurements and the
value of the prognostic score
We assessed the interaction between the prognostic score for
each outcome and the number of K+ measurements made during
follow-up (using tertiles of K+ measurements; online supplemen-
tary Table S4). We identified a significant interaction for all the
outcomes examined in EMPHASIS-HF and EPHESUS (all P< 0.05
for CV mortality, HF hospitalization and all-cause mortality).
Overall, the association between the risk score (per 10 point
increase) and outcome increased with an increasing number of
K+ measurements. In EPHESUS, the HR for CV death ranged
from 2.05 (1.91–2.19) in the first tertile of K+ measurements to
3.77 (3.18–4.46) and 3.86 (3.34–4.46) in the second and third
tertiles. In EMPHASIS-HF the HR for CV death increased from
1.92 (1.63–2.25) in the first tertile to 2.96 (2.27–3.87) in the third
tertile.
Sensitivity analyses
We identified significant interactions between systolic blood
pressure, heart rate, NYHA class with the time after measure-
ment (<30 days or ≥30 days) for CV death; this was not seen for
other variables (online supplementary Table S5). The association
between K+ and CV death was as follows: <30 days, HR 2.57
(1.64–4.04) for K+ > 5.5 mmol/L; ≥30 days, HR 1.26 (0.56–2.89)














































.. In contrast, we identified a significant interaction between K+
and time after measurement for worsening HF hospitalization.
Both hypo- and hyperkalaemia were strongly and significantly
associated with this outcome <30 days but not for the ≥30 day
period (<30 days: HR 2.62 (1.74–3.94) for K+ < 3.5 mmol/L, 2.63
(1.73–4.01) for K+ > 5.5 mmol/L; ≥30 days: HR 0.86 (0.27–2.71)
for K+ < 3.5 mmol/L, 1.39 (0.56–3.45) for K+ > 5.5 mmol/L)
(online supplementary Table S6).
In an additional analysis, we assessed the association of
time-updated serum K+ and eGFR with outcomes further adjust-
ing for dose of MRA and loop diuretics during follow-up in the
EPHESUS trial. The association between hyper- and hypokalaemia,
as well as eGFR, and outcomes remained unchanged (online
supplementary Table S7).
Discussion
To our knowledge this is the first attempt to integrate serial K+
measurements in the context of initiation and maintenance of MRA
treatment in a risk model. The model was created using data
from a cohort of patients with AMI complicated by a reduced
left ventricular ejection fraction and HF and validated in a second,
chronic HF, population. A computerized score has been derived
from the risk model and made available as an online tool for
convenience of use. Furthermore, a sensitivity analysis identified
that highest or lowest values of K+ carried a particularly high risk
for events occurring within 30 days, which strengthens the clinical
relevance of our findings.
Importantly, we hope that this tool will enable a better use of
MRAs by the medical community, avoiding unnecessary permanent
discontinuations. Our risk score has several advantages compared
© 2020 European Society of Cardiology
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Figure 2 Predicted vs. observed risk by deciles of risk score in the EPHESUS derivation cohort (A, C) and EMPHASIS-HF (B, D) validation
cohort. CV, cardiovascular; GOF, goodness of fit; HF, heart failure.
to previous ones. It is time-updated in contrast with all/most of
the previously published risk scores for HF.14,17–19 This method-
ological feature permitted us to precisely evaluate the association
between repeated K+ concentrations and CV outcomes. This asso-
ciation could not be evaluated with previous risk scores as hyper-
and hypokalaemia were usually exclusion criteria in clinical trials.
Including time-updated variables in risk estimation is clinically fea-
sible since patients are repeatedly reviewed in routine practice,
and serial serum K+ monitoring is strongly advised in HF guide-
lines. Our approach is also relevant, since initiation and discontin-
uation of HF therapies such as MRAs during the patient clinical



















.. As a result, the initiation and subsequent adjustment of MRA is
included in our score and the potential negative effect of stopping
this treatment is also estimated. In the Seattle Heart Failure Model
(SHFM) score,17 the benefits of using a MRA were indirectly esti-
mated from large published randomized trials and meta-analyses.
In the Seattle Post Myocardial Infarction Model (SPIM) score,14
the effect of MRA use on CV outcomes was not directly evalu-
able as it was a component of a variable entitled ‘number of
cardiac evidence-based medicines’ (ranging from 0 to 5), with
four other HF treatments including aspirin, beta-blocker, statin,
angiotensin-converting enzyme inhibitors (ACEi)/angiotensin
receptor blockers (ARBs). Moreover, medications are accounted
for in SPIM only at a single time point.
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Adding time-updated variables, including K+ and MRA treatment,
improved risk prediction of CV death (on top of the MAGGIC
score16) in patients with HF eligible for renin–angiotensin system
inhibitors and MRA therapy. We however acknowledge the value
of others comparing scores on their more modern-day databases
in the future.
The present risk score was developed using data from a cohort
of patients with AMI complicated by a reduced left ventricular
ejection fraction and HF and validated in a second, chronic HF,
population. This emphasizes its wide applicability to patients with
HFrEF regardless of the setting (i.e. de novo ischaemic HF, chronic
HF). This validation process contrasts with other scores developed
previously in HF patients.
Independent of history, clinical and laboratory parameters,
and treatment parameters (diuretics, beta-blockers, MRA initia-
tion and maintenance), patients with an abnormal K+ displayed
poorer outcomes. These results corroborate and strengthen
previous results. In a retrospective cohort study using the Cerner
Health Facts database, which included 38 689 patients with
biomarker-confirmed AMI admitted to 67 US hospitals between
1 January 2000 and 31 December 2008, Goyal et al.6 reported a
U-shaped relationship between mean post-admission serum K+
level and in-hospital mortality that persisted after multivariable
adjustment. A large proportion (19.2% to 47.8%) of the AMI patient
population reported in this registry had a history of HF. Unfortu-
nately, Goya et al. did not report on MRA use in their patient pop-
ulation and therefore their results were not adjusted for MRA use.
Our results further show the benefit of initial and sustained
MRA intake over time in the post-AMI population, irrespective
of serum K+ concentrations measured anytime during follow-up,
since patients not assigned MRA or who discontinued MRA dis-
played a poorer prognosis, with no significant interaction (data
not shown). Furthermore, the prognostic value of serum K+ any-
time below or higher than the normal range of 4–5 mmol/L in
this post-AMI and left ventricular systolic dysfunction setting was
observed independent of the prognostic value of eGFR with no
significant interaction (data not shown).
In the chronic HF setting, we previously reported in the
EMPHASIS-HF cohort that incident hypokalaemia below K+ of
4 mmol/L during follow-up was common (42.6%), suggesting that
physicians may not be fully aware of the risk associated with mild
hypokalaemia and therefore not take action to maintain normal
K+. Indeed, patients with hypokalaemia during follow-up were
at increased risk of CV death and/or HF hospitalization. They
had a better prognosis when treated with the MRA eplerenone
compared with placebo.20 In the subset of patients with baseline
hypokalaemia, a significantly greater percentage of patients in the
eplerenone group exhibited a serum K+ ≥4.0 mmol/L at 1 month
than in the placebo group. A mediation analysis showed that
the increase in K+ >4.0 mmol/L at 1 month after randomization
accounted for 26.0% (0.6–51.4%) of the effect of eplerenone
treatment (P = 0.04).20 Conversely, episodes of hyperkalaemia or
worsening renal function were common in these patients receiving
optimal therapy, including ACEi/ARBs and beta-blockers. The addi-
tion of the MRA eplerenone increased the rate of worsening renal



















































































.. did not negate the major survival benefit of eplerenone when
electrolyte and kidney function were systematically monitored,
and eplerenone doses were adjusted based on renal function and
K+ concentration.21 Numerous registries have reported a large
and persistent gap between real-life practice in the use of life-saving
evidence-based therapies, such as RAAS inhibitors, beta-blockers,
MRAs,22 and recommended practices in international guidelines
in patients with HFrEF,23 while it is acknowledged that there are
varying levels of evidence for goal-directed therapies for HF in the
chronic kidney disease population, with a relative paucity of data
in patients with advanced chronic kidney disease,24 who are more
prone to experience hyperkalaemia25 and/or worsening renal
function among RAAS inhibitor users. The fear of inducing hyper-
kalaemia and/or worsening renal function represents the main
trigger of this underuse.26 Of note, the combined use of RAAS
inhibitors, loop diuretics and non-steroidal anti-inflammatory
drugs in the community increases the risk of developing acute
kidney injury.27 Importantly, a recent US study showed that
patients with community acquired acute kidney injury (CA-AKI:
2.5% among 210 895 adults) – as defined by a serum creatinine
increase ≥0.3 mg/dL or≥1.5 times the baseline for consecutive
values – were at approximately twofold the risk of de novo HF
hospitalization (within 90, 180, and 365 days) compared with those
who did not have CA-AKI.28
There are guideline recommendations for the frequency of K+
monitoring in patients with HF administered a RAAS inhibitor29
as well as suggestions regarding the frequency of K+ monitoring
in patients with hyperkalaemia receiving a K+-lowering agent.30
Importantly, the present results stemmed from trials where K+
was monitored serially (median number of K+ measurements was
8.2 per patient per year in EPHESUS and 4.5 in EMPHASIS-HF). To
ascertain that the performance of our score was not mostly driven
by the frequency/number of biological measurements performed
during the trial, we performed an interaction analysis. It showed
that our score was significantly associated with CV outcomes,
regardless of the number of biological measurements made (as
assessed by tertile of measurements). However, we identified
that the association of the score with CV outcome was strongest
in patients with the highest numbers of measurements [HR per
10 point increase in score = 2.05 (1.91–2.19) P< 0.0001 in the
lowest measurement tertile vs. HR 3.86 (3.34–4.46), P< 0.0001
in the highest measurement tertile in EPHESUS]. It should be
acknowledged that most biological measurements were per-
formed according to protocol guidelines [i.e. were mainly routine
measurements rather than triggered by previous K+ perturbations
or worsening clinical status – 11 (9–13) and 8 (5–11) total
measurements in EPHESUS and EMPHASIS-HF vs. 10 (8–11) and
7 (5–10) routine/anticipated measurements]. In our view this
should be perceived as a strength of our study as the biological
monitoring of our patients is in line with current international
guidelines but it does limit the generalizability of our results to
patients in whom routine systematic biological monitoring is
performed, which unfortunately is rare.31,32 In addition, as the
association was strongest in patients with the highest number of
available biological measurements the score we propose performs
best in patients with the most biological information available.
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It is hoped that availability of new safe and well tolerated
K+-lowering agents such as the recently approved patiromer and
sodium zirconium cyclosilicate will reduce the risks of hyper-
kalaemia associated with MRA use and potentially could enable
the long-term use of MRAs in chronic HF patients despite the
occurrence of hyperkalaemia.24 However, inappropriate use may at
least theoretically be associated with more frequent hypokalaemia.
Therefore, the long-term risks and benefits of strategies using
K+-lowering agents will require adequately powered prospective
CV outcome trials.7 The widespread fear of inducing or worsening
hyperkalaemia whilst prescribing or maintaining renin–angiotensin
system inhibitors and MRAs is frequently associated with therapeu-
tic inertia. A recent observational study including all Stockholm
citizens initiating MRA therapy during 2007–2010 assessed the
1-year incidence of clinical hyperkalaemia, and quantified drug pre-
scription changes after an episode of hyperkalaemia.33 Within a
year, 18.5% of patients experienced at least one detected episode
of hyperkalaemia (K+> 5.0 mmol/L), the majority within the first
3 months of therapy. Development of hyperkalaemia was associ-
ated with a four-fold significantly higher risk of mortality overall,
while the results were consistent in the subpopulation of patients
with HF. After hyperkalaemia, 47% discontinued MRA and only 10%
reduced the prescribed dose. Strikingly, when MRA was discontin-
ued, most patients (76%) were not reintroduced to therapy during
the subsequent year.
We expect that the present risk score may raise awareness of
physicians about the CV risk associated with K+ concentrations
outside of the normal range, emphasizes the importance of fre-
quent monitoring and provides a simple tool for adopting strategies
for maintaining them in the normal range, rather than discontinuing
renin–angiotensin system inhibitors and MRAs, which may not be
appropriate. We propose that this easy-to-use score may enable
a better physician’s use of MRAs and adherence to guidelines,
thereby contributing to renewed efforts on education/promotion
about these drugs, their indications, and need for follow-up and
monitoring.33
A prospective study will however be required to establish
whether or not the use of this online calculator will help raise
awareness and improve decision-making regarding the initiation,
maintenance and dose adjustment of renin–angiotensin system
inhibitors and MRAs, and K+ binders, and thereby ultimately
improve CV outcomes in post-AMI and HF or in chronic HF
patients.
Limitations
First, this was a post-hoc analysis. However, our data were derived
from large randomized controlled trials with a rigorous prospective
collection of serum creatinine, serum K+, along with clinical param-
eters, in which clinical events were adjudicated by endpoint com-
mittees. Since the K+-derived and MRA intake prediction model
was developed and validated in two clinical trial populations, it will
necessarily need to be validated in a more generalized community
population. Of note, our risk score was developed in populations
where most patients were treated with ACEi/ARBs, therefore its



















































































.. be confirmed. Our score specifically addresses risk prediction of
patients with HFrEF in contrast to the MAGGIC score.16 A num-
ber of variables were considered as time-varying in our models.
However, CV risk factors were not re-assessed during the course
of the trial. This is a limitation to our analysis. Finally, the recovery
of left ventricular function particularly in patients post-AMI was
not captured and this could have a strong influence not only on
concurrent care but also on the outcomes.
Conclusions
Adding time-updated variables including K+ concentrations and
MRA intake improved the prediction of CV death in patients with
HF eligible for renin–angiotensin system inhibitors and MRA ther-
apy. The risk score encompassing repeat K+ concentrations and
initiation and discontinuation of MRA therapy may help physicians
to better use MRAs, avoid unnecessary and potentially detrimental
permanent discontinuations, and therefore improve CV outcomes.
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